Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.2% |
| 2 | Technology | 14.19% |
| 3 | Financials | 12.33% |
| 4 | Consumer Staples | 10.22% |
| 5 | Industrials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1826
Orion Group Holdings
ORN
$402M
| $4.17M | 0.01% |
558,300
-83,400
| -13% | -$623K |
|
1827
Axogen
AXGN
$2.62B
| $4.17M | 0.01% |
248,800
+107,849
| +77% | +$1.45M |
|
1828
Tyler Technologies
TYL
$13.5B
| $4.17M | 0.01% |
23,713
-129,360
| -85% | -$21.5M |
|
|
RESI
1829
DELISTED
Front Yard Residential Corporation Common Stock
RESI
| $4.16M | 0.01% |
321,374
-386,326
| -55% | -$5.48M |
|
|
BGC
1830
DELISTED
General Cable Corporation
BGC
| $4.15M | 0.01% |
253,900
-191,600
| -43% | -$3.24M |
|
1831
Tilly's
TLYS
$122M
| $4.15M | 0.01% |
408,700
-161,000
| -28% | -$1.53M |
|
|
ACBI
1832
DELISTED
Atlantic Capital Bancshares, Inc. Common Stock
ACBI
| $4.14M | 0.01% |
218,160
-21,607
| -9% | -$407K |
|
1833
Verastem
VSTM
$596M
| $4.14M | 0.01% |
158,300
+56,083
| +55% | +$1.43M |
|
|
PHIIK
1834
DELISTED
PHI, Inc. Non-Voting Common Stock
PHIIK
| $4.14M | 0.01% |
423,900
+108,900
| +35% | +$1.15M |
|
1835
RLI Corp
RLI
$5.85B
| $4.13M | 0.01% |
151,400
+110,208
| +268% | +$3.1M |
|
1836
DHI Group
DHX
$171M
| $4.13M | 0.01% |
1,448,300
+233,500
| +19% | +$769K |
|
|
PMBC
1837
DELISTED
Pacific Mercantile Bancorp
PMBC
| $4.12M | 0.01% |
468,400
+34,300
| +8% | +$271K |
|
1838
SEI Investments
SEIC
$12.8B
| $4.12M | 0.01% |
+76,626
| New | +$3.95M |
|
|
NOA
1839
North American Construction
NOA
$375M
| $4.12M | 0.01% |
935,500
-132,800
| -12% | -$620K |
|
|
AMNB
1840
DELISTED
American National Bankshares Inc
AMNB
| $4.11M | 0.01% |
111,100
+12,800
| +13% | +$473K |
|
|
CPN
1841
DELISTED
Calpine Corporation
CPN
| $4.09M | 0.01% |
302,545
-1,013,213
| -77% | -$12.2M |
|
|
DX
1842
Dynex Capital
DX
$3.24B
| $4.09M | 0.01% |
192,092
+34,492
| +22% | +$720K |
|
1843
Townsquare Media
TSQ
$104M
| $4.09M | 0.01% |
399,600
-19,931
| -5% | -$215K |
|
|
UCP
1844
DELISTED
UCP, Inc.
UCP
| $4.09M | 0.01% |
373,700
+64,561
| +21% | +$715K |
|
1845
Altisource Portfolio Solutions
ASPS
$64.4M
| $4.09M | 0.01% |
23,438
+13,588
| +138% | +$2.7M |
|
1846
Standex International
SXI
$4.01B
| $4.08M | 0.01% |
45,000
-3,600
| -7% | -$327K |
|
1847
The RMR Group
RMR
$346M
| $4.08M | 0.01% |
83,800
+44,800
| +115% | +$2.26M |
|
1848
Autoliv
ALV
$8.94B
| $4.07M | 0.01% |
+51,495
| New | +$3.9M |
|
|
GSH
1849
DELISTED
Guangshen Railway Co. Ltd
GSH
| $4.07M | 0.01% |
163,500
+15,900
| +11% | +$439K |
|
|
JOBS
1850
DELISTED
51job Inc
JOBS
| $4.06M | 0.01% |
90,857
-298
| -0.3% | -$12.7K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.